Straits Times Index
3,174.35 -13.31 (-0.42%) Nikkei
37,136.45 -943.25 (-2.48%) Hang Seng
16,185.71 -200.16 (-1.22%) FTSE 100
7,877.05 +29.06 (+0.37%) Bitcoin USD
61,921.38 +351.92 (+0.57%) CMC Crypto 200
1,280.93 +395.39 (+43.16%)
ANI Pharmaceuticals, Inc. (ANIP)
After hours:
| Previous close | 65.48 |
| Open | 65.36 |
| Bid | 64.51 x 100 |
| Ask | 64.78 x 100 |
| Day's range | 64.43 - 65.97 |
| 52-week range | 36.99 - 70.81 |
| Volume | |
| Avg. volume | 143,382 |
| Market cap | 1.355B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 75.98 |
| EPS (TTM) | 0.85 |
| Earnings date | 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 79.80 |
GlobeNewswireANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
BAUDETTE, Minn., April 18, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2024 financial results on Friday, May 10, 2024, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows: DateFriday, May 10, 2024 Time8:30 a.m. ET T
ZacksSage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.
ZacksGSK Announces FDA Acceptance of New Meningococcal Jab BLA
The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.
